Difference between revisions of "Mast cell leukemia"

Jump to: navigation, search
(Natural History, Complications, and Prognosis)
Line 26: Line 26:
  
 
==[[Mast cell leukemia natural history, complications, and prognosis|Natural History, Complications, and Prognosis]]==
 
==[[Mast cell leukemia natural history, complications, and prognosis|Natural History, Complications, and Prognosis]]==
 
{{CMG}}; {{AE}} {{S.G.}}
 
 
==Overview==
 
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
 
 
OR
 
 
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
 
 
OR
 
 
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
 
==Natural History, Complications, and Prognosis==
 
 
===Natural History===
 
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
 
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
 
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
 
 
===Complications===
 
*Common complications of [disease name] include:
 
**[Complication 1]
 
**[Complication 2]
 
**[Complication 3]
 
 
===Prognosis===
 
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
 
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
 
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
 
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
 
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
 
 
==References==
 
{{Reflist|2}}
 
 
{{WH}}
 
{{WS}}
 
 
[[Category: (name of the system)]]
 
[[Category: (name of the system)]]
 
==Overview==
 
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
 
 
OR
 
 
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
 
 
OR
 
 
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
 
==Natural History, Complications, and Prognosis==
 
 
===Natural History===
 
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
 
*The symptoms of (disease name) typically develop ___ years after exposure to ___.
 
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
 
 
===Complications===
 
*Common complications of [disease name] include:
 
**[Complication 1]
 
**[Complication 2]
 
**[Complication 3]
 
 
===Prognosis===
 
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
 
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
 
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
 
*[Subtype of disease/malignancy] is associated with the most favorable prognosis.
 
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
 
 
==References==
 
{{Reflist|2}}
 
 
{{WH}}
 
{{WS}}
 
 
[[Category: (name of the system)]]
 
[[Category: (name of the system)]]
  

Revision as of 11:55, 22 October 2018

Mast cell leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mast cell leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mast cell leukemia On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mast cell leukemia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mast cell leukemia

CDC on Mast cell leukemia

Mast cell leukemia in the news

Blogs on Mast cell leukemia

Directions to Hospitals Treating Mast cell leukemia

Risk calculators and risk factors for Mast cell leukemia

For patient information click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Synonyms and Keywords: Mast cell blood cancer; Mast cell cancer; Mastocyte cancer; Mastocyte leukemia; Malignant mastocytosis; Mastocyte blood cancer; Basophilic leukemia

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mast cell leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | MRI| Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case#1

References


Linked-in.jpg